Neuronal Exosome Biomarkers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Biomarker Name | Neuronal Exosome Biomarkers |
|---|---|
| Category | Fluid Biomarkers - Blood/CSF |
| Target | Neural-derived exosomal proteins and RNAs |
| Sample Type | Blood (plasma/serum), CSF |
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia |
| Clinical Utility | Diagnosis, Progression, Treatment Response |
Neuronal exosome biomarkers represent a cutting-edge approach to detecting and monitoring neurodegenerative diseases through analysis of small extracellular vesicles (EVs) released by neural cells[1]. These exosomes carry a cargo of proteins, lipids, and nucleic acids that reflect the molecular state of their parent cells, providing a "snapshot" of brain pathology through peripheral biofluids.
Exosomes are small extracellular vesicles (30-150 nm) that are released by virtually all cell types, including neurons and glia[2]:
| Cell Type | Exosome Markers | Detection Method |
|---|---|---|
| Neurons | L1CAM (CD171), NCAM, Synaptophysin | Flow cytometry, ELISA |
| Astrocytes | GFAP, AQP4 | Immunoprecipitation |
| Microglia | CD68, IBA1 | Antibody capture |
| Oligodendrocytes | MBP, PLP | Western blot |
| Biomarker | Source | Change in AD | Clinical Significance |
|---|---|---|---|
| p-tau181 | Plasma exosomes | Increased | Diagnostic, progression |
| p-tau217 | Plasma exosomes | Increased | High diagnostic accuracy |
| Aβ42 | Plasma exosomes | Increased | Reflects brain amyloid |
| SNAP-25 | CSF exosomes | Decreased | Synaptic dysfunction |
| NF-L | Plasma exosomes | Increased | Neurodegeneration |
| Biomarker | Change in PD | Notes |
|---|---|---|
| α-Synuclein | Increased | Oligomeric forms |
| LRRK2 | Increased | Risk-specific |
| DJ-1 | Decreased | Oxidative stress marker |
| Tau | Increased | Disease progression |
| Neurofilament light (NfL) | Increased | Disease severity |
| Method | Yield | Purity | Time |
|---|---|---|---|
| Ultracentrifugation | High | Low | 4-6 hours |
| Size-exclusion chromatography | Moderate | High | 1-2 hours |
| Immunocapture (L1CAM) | Low-moderate | Very high | 2-3 hours |
| Precipitation (ExoQuick) | High | Moderate | 30 min |
| Feature | Neuronal Exosomes | CSF Biomarkers | PET Imaging |
|---|---|---|---|
| Invasiveness | Low (blood) | High (lumbar) | Moderate (radiation) |
| Cost | Moderate | Moderate | High |
| Accessibility | High | Moderate | Low |
| Specificity | High | High | Moderate |
| Spatial info | No | No | Yes |
The study of Neuronal Exosome Biomarkers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Fiandaca MS, et al. Identification of preclinical Alzheimer's disease by cerebrospinal fluid analysis of amyloid and tau biomarkers. Nat Med. 2015;21(2):218-229. PMID:25614023 ↩︎
Théry C, et al. Isolation and characterization of exosomes from cell culture media and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3.22. PMID:18228523 ↩︎